MYRIAD GENETICS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M |
| Gross profit | $576.6M | $585.4M | $517.0M | $476.4M | — |
| Operating income | -$387.2M | -$123.5M | -$257.4M | -$140.6M | -$190.5M |
| Operating expenses | $963.8M | $708.9M | $774.4M | $617.0M | — |
| Cost of revenue | $247.9M | $252.2M | $236.2M | $202.0M | — |
| Cash from operations | $1.8M | -$8.7M | -$110.9M | -$106.3M | $18.6M |
| Capital expenditure | — | — | — | $45.3M | $18.0M |
| Free cash flow | — | — | — | -$151.6M | $600,000 |
| Share repurchases | — | — | — | — | $0 |
| Impairments | $319.4M | $56.6M | $0 | $16.9M | $0 |
| Total assets | $706.6M | $1.0B | $1.1B | $1.2B | $1.3B |
| Total liabilities | $338.6M | $326.5M | $363.3M | $312.9M | $352.9M |
| Total debt | $125.0M | $40.5M | — | — | — |
Shares outstanding 94.4M · Free float 98.0%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.